CN108392506A - The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application - Google Patents
The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application Download PDFInfo
- Publication number
- CN108392506A CN108392506A CN201810504023.4A CN201810504023A CN108392506A CN 108392506 A CN108392506 A CN 108392506A CN 201810504023 A CN201810504023 A CN 201810504023A CN 108392506 A CN108392506 A CN 108392506A
- Authority
- CN
- China
- Prior art keywords
- wilsonii
- extracting method
- extract
- added
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The application belongs to natural products technical field, and in particular to the extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application.Extracting method provided by the invention includes：A) alcoholic solution is added in dry wilsonii crushed products, carries out ultrasonic extraction, be concentrated under reduced pressure, obtain alcohol extract；B) sulfuric acid solution is added in alcohol extract, is acidified, obtain acidizing product；C) water phase is added in acidizing product, mixing adds organic phase and extracted, and collects organic extractant phase object, is concentrated to give medicinal extract；D) medicinal extract is diluted, upper large pore resin absorption column with water dissolution, then uses water and alcoholic solution as eluent successively, collects eluent, concentration.Compared with prior art, extracting method extraction efficiency provided by the present invention is high, purification cycle is short, solvent usage amount is few, and active component content is high.
Description
Technical field
The invention belongs to natural products technical fields, and in particular to a kind of extracting method and medicine of wilsonii activity extract
Compositions and its application.
Background technology
Wilsonii is Araliaceae, is distributed widely in Chinese Heilungkiang, Jilin, Liaoning, Hebei and Shanxi.Wilsonii is
A kind of important Chinese medicine has " bowl spares strengthening the essence, hard muscle in China Chinese Traditional Medicine field in existing long applicating history
The effect of bone, Qiang Zhiyi ".It is reported that wilsonii has antifatigue effect, enhancing endurance and ability, improves alert and resourceful and study
The curative effects such as ability have also been confirmed in human experimentation.Equally there is the report of considerable quantity to point out that it has branch at present
Help immune system, restore improper low blood pressure, improve the circulatory system, make disorderly glycolipid metabolism normalization, liver, bone density and
The effect of anabolism of other vitals.
The chemical composition of wilsonii, including：Lignanoid, triterpene, cumarin, flavonoids, organic acid and amino acid etc., these
Chemical composition has various activity, such as：Adjust immune function of human body, it is antitumor, adjust cardiovascular and cerebrovascular, antifatigue and anti-
Aging etc..In order to which the chemical composition by these active effects from wilsonii is extract, people are mainly by adopting at present
It uses water as Extraction solvent, is extracted most of chemical composition in wilsonii by the methods of immersion, reflux or ultrasound,
Obtain siberian Ginseng P.E；Then, the chemical composition in extract is detached successively by polarity size using silica gel column chromatography pure
It dissolves and.Although this method can separate most of active constituent in wilsonii, long time period needs to spend
Take a large amount of organic solvent；Moreover, the active constituent that some are micro, polarity is larger is easily hung on pillar, extraction efficiency compared with
It is low.
Invention content
In order to solve the above-mentioned technical problem, the purpose of the present invention is to provide a kind of extraction sides of wilsonii activity extract
Method and pharmaceutical composition and its application.
The specific technical solution of the present invention is as follows：
A kind of extracting method of wilsonii activity extract, including：
A) alcoholic solution is added in dry wilsonii crushed products, carries out ultrasonic extraction, be concentrated under reduced pressure, obtain alcohol extract；
B) alcohol extract of step a) is added in sulfuric acid solution and is acidified, obtain acidizing product；
C) water phase is added in the acidizing product of step b), mixing adds organic phase and extracted, and collects organic extractant phase
Object is concentrated to give medicinal extract；
D) medicinal extract of step c) is diluted, upper large pore resin absorption column with water dissolution, then uses water and alcoholic solution successively
As eluent, eluent is collected, concentration obtains the wilsonii activity extract.
Preferably, the mass ratio of the sulfuric acid solution and the alcohol extract is 1:(6~40)；
The sulfuric acid concentration of the sulfuric acid solution is 1.5mol/L~2.5mol/L.
Preferably, the frequency of the ultrasound is 60Hz~200Hz；The extraction time is 0.5h~10h, and Extracting temperature is
20 DEG C~80 DEG C.
Preferably, the alcoholic solution is ethanol solution, and mass percent concentration is 10%~70%.
Preferably, the additive amount of the wilsonii crushed products is：1mg~50mg is added in every milliliter of alcoholic solution.
Preferably, the wilsonii activity extract is isofraxidin.
The present invention also provides a kind of pharmaceutical compositions, including：The wilsonii activity extraction obtained by said extracted method
Object and pharmaceutically acceptable auxiliary material.
Preferably, dosage form includes：One kind in syrup, tablet, pill, granule, suspension, aqua and injection
Or it is a variety of.
The present invention also provides aforementioned preparation process and/or described pharmaceutical composition to prepare the application in sleeping drug.
Compared with prior art, extracting method tool provided by the present invention has the advantage that：
1) ultrasound can destroy the molecular structure of wilsonii, and more active constituents is promoted to be dissolved in alcoholic solution, use
The method of alcoholic solution combination ultrasonic extraction, improves the extraction efficiency of active constituent；
2) compared with silica gel column chromatography separating purification, wilsonii is substantially shorter using macroporous resin column chromatography concentration method and is lived
Property extract purification cycle, and eluted only with water and alcoholic solution equal solvent, green is mild, easily recycling, reduces
The usage amount of organic reagent；
3) use alcoholic solution as eluant, eluent, under most of big polar active ingredients can be eluted from large pore resin absorption column
Come, active constituent residual quantity is low, and extraction efficiency is high.
Description of the drawings
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technology description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
The embodiment of invention for those of ordinary skill in the art without creative efforts, can also basis
The attached drawing of offer obtains other attached drawings.
Fig. 1 is the photo of standard items, sample 1, sample 2 and sample 3 under 365nm fluorescence；
Fig. 2 is the photo of standard items, sample 1, sample 2 and sample 3 under 254nm fluorescence.
Specific implementation mode
Below in conjunction with the embodiment of the present invention, technical scheme of the present invention is clearly and completely described, it is clear that
Described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based on the implementation in the present invention
Example, every other embodiment obtained by those of ordinary skill in the art without making creative efforts belong to
The scope of protection of the invention.
Embodiment 1
A kind of extracting method for wilsonii activity extract that the present embodiment is provided, including：
1, dry acanthopanax coarse powder 25g is taken, 50% ethyl alcohol of 500mL is added, and repeated ultrasonic is extracted at 40 DEG C,
Extraction total duration is 4h, obtains alcohol extract；Wherein, ultrasonic frequency is 100Hz, each ultrasound 30min.
2, the sulfuric acid solution that sulfuric acid concentration is 2.0mol/L is added in alcohol extract, shaken up, is acidified, filtering obtains acidizing product；
Wherein, the mass ratio of sulfuric acid and alcohol extract is 1:18.
3, water dilution is added in acidizing product, adds chloroform and repeat extraction 3 times, 100mL chloroforms is added every time, merge chlorine
It is imitative, medicinal extract is concentrated under reduced pressure to obtain；Extraction residue is in methanol solution transfer to container；
4, medicinal extract is diluted with water dissolution, is pumped into 12-1 large pore resin absorption columns and is adsorbed with constant flow pump；Then it uses
Water elution is collected eluent, is concentrated to give wilsonii activity extract with 70% ethanol elution again later.
In the present embodiment, the leaching of the ingredients such as starch, protein and mucus can avoid as Extraction solvent using ethyl alcohol
Go out；Add water to extract, the impurity such as resin in alcohol extract, fat-soluble pigment can be removed, it is active constituent-enriched.
Embodiment 2
The extracting method that the present embodiment is provided compared with Example 1, difference lies in：
The mass ratio of sulfuric acid and the alcohol extract is 1:9；
The frequency of ultrasound is 60Hz9；The ultrasonic extraction time is 30min, and Extracting temperature is 30 DEG C；
Alcoholic solution is ethanol solution, mass percent concentration 20%；
The additive amount of wilsonii crushed products is：20mg is added in every milliliter of alcoholic solution.
Remaining place is substantially similar to embodiment 1, no longer repeats one by one herein.
Embodiment 3
The extracting method that the present embodiment is provided compared with Example 1, difference lies in：
The mass ratio of sulfuric acid and the alcohol extract is 1:36；
The frequency of ultrasound is 200Hz；The ultrasonic extraction time is 3h, and Extracting temperature is 60 DEG C；
Alcoholic solution is ethanol solution, mass percent concentration 70%；
The additive amount of wilsonii crushed products is：20mg is added in every milliliter of alcoholic solution.
Remaining place is substantially similar to embodiment 1, no longer repeats one by one herein.
Comparative example 1
It by using water as Extraction solvent, is heated to reflux after immersion, most of chemical composition in wilsonii is extracted
Out, wilsonii water extract is obtained；
Then, the chemical composition in extract is divided by polarity size by different eluents successively using silica gel column chromatography
From being purified.
Although this method can separate most of active constituent in wilsonii, long time period needs
Spend a large amount of organic solvent；Moreover, the active constituent that some are micro, polarity is larger is easily hung on pillar, extraction efficiency
It is relatively low.
Embodiment 4
Weigh 1.4mg isofraxidins standard items (Nat'l Pharmaceutical ＆ Biological Products Control Institute, batch number:1482-201409),
The clear yellow solution that 10% ethanol solutions of 5mL are configured to a concentration of 0.28mg/mL is added, as standard items；
The ethanol solution for weighing 0.1431g Manyprickle Acanthopanax Roots addition 5mL 10% is configured to the palm fibre of a concentration of 28.62mg/mL
Color solution, as sample 1；
The wilsonii water extract of 1.1058g comparative examples 1 is weighed, 10% ethyl alcohol is added and is settled to 10mL, as sample 2；
The siberian Ginseng P.E of the preparation of 0.2847g embodiments 1 is weighed, 10% ethyl alcohol is added and is settled to 10mL, as sample
3。
On silica gel plate after contact plate, petroleum ether is used：Ethyl acetate=1：1 is used as solvent, then in fluorescent lamp (wavelength
It is observed under 365nm), as shown in Figure 1, finding that apparent blue-fluorescence spot, while sample occur at Rf=0.48 in standard items
1, sample 2 and sample 3 can also be observed that apparent blue-fluorescence spot, thus sample 1, sample 2 and sample 3 at Rf=0.48
Contain isofraxidin, is the characteristic component of siberian Ginseng P.E.In addition to the characteristic spots of the isofraxidin,
As depicted in figs. 1 and 2, sample 1, sample 2 and sample 3 also show multiple spots under the wavelength of 365nm and 254nm
Point.Wherein, the spot shown with sample 2 is more, illustrates that the method for extraction and purification effect for passing through comparative example 1 is poor, what is obtained carries
Take impurity in object more, active constituent concentration effect is poor.
Embodiment 5
Activity characteristic ingredient in using isofraxidin as wilsonii activity extract, using high effective liquid chromatography for measuring
The content of isofraxidin in extract, the content for measuring isofraxidin are up to 11.06%, and extraction efficiency is high.
Table 1
| Determination of isofraxidin (%) | |
| Embodiment 1 | 1.12 |
| Embodiment 2 | 0.57 |
| Embodiment 3 | 1.23 |
| Comparative example 1 | 0.66 |
Embodiment 6 promotees sleep experiments
1, sample is grouped
A, B groups：It is determined by 200mg/ people, 5mg/kg.BW is divided into three groups basic, normal, high with 10,20,40 times；10μL/g.BW
Gavage；Sample 3 (embodiment 1) is dissolved in deionized water be configured to a concentration of 5mg/mL, 10mg/mL, 20mg/mL as
Basic, normal, high concentration group.
C groups：It is determined by 200mg/ people, 5mg/kg.BW is divided into four groups with 10,20,40,80 times；10 μ L/g.BW gavages；It will
Sample 2 (comparative example 1), which is dissolved in deionized water, to be configured to a concentration of 5mg/mL, 10mg/mL, 20mg/mL, 40mg/mL to divide to be four
Group.
2, mice group
A groups：Yellow Jackets Sleep latency is tested and yellow Jackets sleeping time tests every group of 5 mouse, each group
Mouse according to 10 μ L/g.BW dosage continuous gavage 14 days.
B groups：Every group of 5 mouse, the experiment of barbital sodium Sleep latency and bar ratio are tested in barbital sodium sub-threshold dose hypnosis
Appropriate sodium sleeping time tests every group of 5 mouse, each group mouse according to 10 μ L/g.BW dosage continuous gavage 10 days.
C groups：Yellow Jackets Sleep latency is tested and yellow Jackets sleeping time tests every group of 5 mouse, each group
Mouse according to 10 μ L/g.BW metering continuous gavage 10 days.
3, sleep experiments
(1) preliminary experiment
A, yellow Jackets/barbital sodium sub-threshold dose hypnosis trial test：It determines and is urged under yellow Jackets/barbital sodium threshold
The yellow Jackets that dormancy dosage, the i.e. righting reflex of 80-90% mouse do not disappear/barbital sodium maximum sub-threshold dose；
B, yellow Jackets/barbital sodium Sleep latency trial test：Determining makes animal 100% fall asleep, but does not make to sleep
The yellow Jackets of dormancy overlong time/barbital sodium dosage；
C, extend yellow Jackets/barbital sodium sleeping time preliminary experiment:Determining makes animal 100% fall asleep, but does not make
Sleeping time long yellow Jackets/barbital sodium dosage.
(2) formal test
A, direct sleep experiments：The quantity for observing the mouse for entering sleep in gavage 30min, judges mice sleep to right
Areflexia is index (when mouse is placed in quilt, can right body position immediately.If it exceeds 30-60s cannot the person of righting, that is, recognize
For righting reflex loss, mouse enters sleep), compare the influence that wilsonii directly sleeps to each tested material.
B, yellow Jackets/barbital sodium sub-threshold dose hypnosis test：After last gavage after 30min, threshold is injected intraperitoneally
Yellow Jackets/barbital sodium of lower dosage enters sleep by mouse of mouse righting reflex loss, observes mouse in 30min
The number of elements of sleep, calculates sleep rate, and more each tested material falls asleep to the mouse for contacting sub-threshold dose yellow Jackets/barbital sodium
The influence of rate.
C, yellow Jackets Sleep Latency Test：After last gavage after 30min, intraperitoneal injection yellow Jackets/bar
Than appropriate sodium, observe and record from injection yellow Jackets/barbital sodium to the time of righting reflex loss, i.e. Sleep latency.Than
Mice sleep preclinical influence of more each tested material on contact yellow Jackets/barbital sodium.
D, extend yellow Jackets/barbital sodium sleeping time experiment：After last gavage after 30min, intraperitoneal injection penta
Barbital sodium/barbital sodium enters sleep by mouse of mouse righting reflex loss, and observation disappears since righting reflex to extensive
Multiple time, i.e. sleep time.Compare each tested material to contacting the mouse sleep time of yellow Jackets/barbital sodium
It influences.
4, interpretation of result
(1) sleep experiments -1
Such as Tables 1 and 2 it is found that Sleep latency increasing in downward trend with wilsonii concentration, wherein a concentration of
5mg/mL (p compared with blank group>0.05), then without significant difference, when concentration increases to 10mg/mL and 20mg/mL with
Blank group compares (p<0.05) Sleep latency for, significantly reducing mouse contributes to the sleep of mouse.
Sleeping time increases with wilsonii concentration in the trend risen, and three concentration more have (p with blank group
<0.05), i.e., with blank group than the more significant sleeping time for extending mouse, contribute to the sleep of mouse.
The processing of 1 A group Sleep latencies of table
2 A group sleeping times of table are handled
(2) sleep experiments -2
By table 3 and table 4 it is found that the sleep rate of mouse increases with the raising of wilsonii concentration, i.e. fall asleep in 30min
Mouse quantity increases, and illustrates that wilsonii contributes to the sleep of mouse.
Sleep latency is as the raising of wilsonii concentration is in the trend reduced, wherein a concentration of 5mg/mL and blank group ratio
Compared with (p>0.05), then without significant difference, and a concentration of 10mg/mL and the 20mg/mL (p compared with blank group<0.05), i.e., with
The more significant difference of blank group, significantly reduces the Sleep latency of mouse, contributes to the sleep of mouse.
Sleeping time with being increased after the reduction of concentration, when concentration increases to 20mg/mL, when extending the sleep of mouse
Between, but compare (p with blank group>0.05) there is no significant difference.
The processing of 3 B group Sleep latencies of table
4 B group sleeping times of table are handled
(3) sleep experiments -3
By table 5 and table 6 it is found that Sleep latency increases no significant change with wilsonii concentration, but works as concentration
When increasing to 40mg/mL compared with blank group (p<0.001) incubation period, is significantly extended, the sleep of mouse is unfavorable for.
Sleeping time reduces afterwards as the raising of wilsonii concentration first increases, when concentration increases to 20mg/mL and blank
Group compares (p<0.05) sleeping time for, significantly extending mouse contributes to the sleep of mouse.
The processing of 5 C group Sleep latencies of table
6 C group sleeping times of table are handled
Integrated comparative experimental result three times, preceding experiment twice is with a collection of siberian Ginseng P.E, and experiment for the first time makes
With yellow Jackets come hypnosis, gavage 14 days can significantly reduce the sleep of mouse when wilsonii concentration increases to 20mg/mL
Incubation period extends the sleeping time of mouse；Second of experiment comes hypnosis, gavage 10 days, when wilsonii concentration using barbital sodium
It can significantly reduce the Sleep latency of mouse when increasing to 10mg/mL and 20mg/mL, can extend when concentration increases to 20mg/mL
The sleeping time of mouse, but effect is not notable；Third time experiment is another batch of siberian Ginseng P.E, uses yellow Jackets
Carry out hypnosis, the change of gavage 10 days, wilsonii concentration does not have much influence Sleep latency and concentration increases to 40mg/mL
Shi Xianzhu extends the incubation period of mouse, is unfavorable for the sleep of mouse, and Sleep latency is almost without change when a concentration of 20mg/mL
The sleeping time that changes but can significantly extend mouse, be conducive to the sleep of mouse.
Integrated comparative, a concentration of 20mg/mL may is that an optium concentration, and at least gavage more than two weeks can reduce
The Sleep latency of mouse extends the sleeping time of mouse, is conducive to the sleep of mouse.As a whole, wilsonii has certain
Promote the effect of sleep, but the ambiguity that mice sleep quality and wilsonii concentration changes is clear, and needs are more
Data are supported to illustrate the effect of wilsonii improves sleep.
Claims (10)
1. a kind of extracting method of wilsonii activity extract, which is characterized in that including：
A) alcoholic solution is added in dry wilsonii crushed products, carries out ultrasonic extraction, be concentrated under reduced pressure, obtain alcohol extract；
B) alcohol extract of step a) is added in sulfuric acid solution and is acidified, obtain acidizing product；
C) water phase being added in the acidizing product of step b), mixing adds organic phase and is extracted, and collects organic extractant phase object,
It is concentrated to give medicinal extract；
D) medicinal extract of step c) is diluted, upper large pore resin absorption column with water dissolution, then uses water and alcoholic solution conduct successively
Eluent, collects eluent, and concentration obtains the wilsonii activity extract.
2. extracting method according to claim 1, which is characterized in that the mass ratio of the sulfuric acid solution and the alcohol extract
It is 1:(6~40)；
The sulfuric acid concentration of the sulfuric acid solution is 1.5mol/L~2.5mol/L.
3. extracting method according to claim 1, which is characterized in that the frequency of the ultrasound is 60Hz~200Hz.
4. extracting method according to claim 1, which is characterized in that the extraction time is 0.5h~10h, Extracting temperature
It is 30 DEG C~80 DEG C.
5. extracting method according to claim 1, which is characterized in that the alcoholic solution is ethanol solution, quality percentage
Specific concentration is 10%~70%.
6. extracting method according to claim 1, which is characterized in that the additive amount of the wilsonii crushed products is：Often
1mg~50mg is added in the milliliter alcoholic solution.
7. extracting method according to claim 1, which is characterized in that the wilsonii activity extract is isofraxidin.
8. a kind of pharmaceutical composition, which is characterized in that including：What the extracting method described in claim 1 to 7 any one obtained
Wilsonii activity extract and pharmaceutically acceptable auxiliary material.
9. pharmaceutical composition according to claim 8, which is characterized in that its dosage form includes：Syrup, tablet, pill,
It is one or more in granula, suspension, aqua and injection.
10. the preparation method and/or claim 8 or 9 described pharmaceutical compositions described in claim 1 to 7 any one are being made
Application in standby sleep drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810504023.4A CN108392506A (en) | 2018-05-23 | 2018-05-23 | The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810504023.4A CN108392506A (en) | 2018-05-23 | 2018-05-23 | The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108392506A true CN108392506A (en) | 2018-08-14 |
Family
ID=63102438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810504023.4A Pending CN108392506A (en) | 2018-05-23 | 2018-05-23 | The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108392506A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679635A (en) * | 2021-08-10 | 2021-11-23 | 楚香(上海)生物科技有限公司 | Acanthopanax senticosus extract for cosmetics and application thereof |
| CN114957358A (en) * | 2020-11-16 | 2022-08-30 | 北华大学 | Lignan glycoside compounds and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1450061A (en) * | 2002-04-10 | 2003-10-22 | 东北林业大学 | Process for extracting Isofraxidin |
-
2018
- 2018-05-23 CN CN201810504023.4A patent/CN108392506A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1450061A (en) * | 2002-04-10 | 2003-10-22 | 东北林业大学 | Process for extracting Isofraxidin |
Non-Patent Citations (3)
| Title |
|---|
| 康施瑶，等: "异嗪皮啶镇静催眠作用的研究", 《中医药学报》 * |
| 汪琢，等: "刺五加中异嗪皮啶提取工艺优化及其抗肿瘤、抗氧化活性研究", 《天然药物研究与开发》 * |
| 郭琪，等: "刺五加提取物大孔树脂精制试验", 《齐鲁药事》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957358A (en) * | 2020-11-16 | 2022-08-30 | 北华大学 | Lignan glycoside compounds and preparation method and application thereof |
| CN114957358B (en) * | 2020-11-16 | 2023-11-03 | 北华大学 | Lignan glycoside compound, and preparation method and application thereof |
| CN113679635A (en) * | 2021-08-10 | 2021-11-23 | 楚香(上海)生物科技有限公司 | Acanthopanax senticosus extract for cosmetics and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106474169B (en) | Celery seed extract, preparation and preparation method thereof | |
| CN102228517B (en) | Plantain seed extract and application thereof | |
| CN101480422A (en) | Tibetan oriental wormwood extract as well as preparation method and use thereof | |
| CN108392506A (en) | The extracting method and pharmaceutical composition of a kind of wilsonii activity extract and its application | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| US20130231469A1 (en) | Method for preparing albiflorin and paeoniflorin | |
| CN102423343A (en) | Broussonetia papyrifera total flavonoids extract, its preparation method and its application | |
| CN101991567A (en) | Application of three biflavone monomer components extracted from ginkgo leaves in preparing medicament of alpha-glucosidase inhibitor | |
| CN110066305B (en) | Mechanochemical extraction method for preparing crude naphthopyrone extract from berchemilla lineate | |
| CN102357110B (en) | New application of Eclipta prostrata L in preparing medicine for preventing and treating hyperlipidemia | |
| CN101919901A (en) | Application of total aglycone of gleditsia sinensis and echinocystic acid in preparation of alpha-glucosidase inhibitor drugs | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN1155592C (en) | Process for preparing total jujuboflavone with calmative and hypnosis action | |
| CN1189176C (en) | Astragalus root methyl-glycoside composition and preparation method | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN102225095B (en) | Effective fraction of plantain seeds as well as preparation method and application thereof | |
| CN101618069B (en) | Capsule preparation for treating bruise as well as bleeding and easing pain and preparation method and use thereof | |
| CN100502867C (en) | Preparation of sinomenine as antineoplastic medicament | |
| CN109876021B (en) | Preparation method of Lyophyllum decastes extract rich in polyacetylene compounds and its blood sugar lowering application | |
| CN107365284A (en) | A kind of method that taxol is extracted from Chinese yew | |
| CN103005282A (en) | Wheat bran extract healthcare food with blood sugar reduction function and preparation method thereof | |
| CN110279738A (en) | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract | |
| CN115737698B (en) | Application of armored grass extract in inhibiting glucosidase | |
| CN102670698A (en) | Application of philippine flemingia root extract in preparation of medicines for preventing and treating diabetes | |
| CN1057300C (en) | Glucoside compound of catechine and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180814 |